Invention Grant
- Patent Title: Formylated N-heterocyclic derivatives as FGFR4 inhibitors
-
Application No.: US16211139Application Date: 2018-12-05
-
Publication No.: US10786492B2Publication Date: 2020-09-29
- Inventor: Nicole Buschmann , Robin Alec Fairhurst , Pascal Furet , Thomas Knoepfel , Catherine Leblanc , Robert Mah
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: NOVARTIS AG
- Current Assignee: NOVARTIS AG
- Current Assignee Address: CH Basel
- Agent David K. Cheung
- Main IPC: C07D401/12
- IPC: C07D401/12 ; C07D401/14 ; A61K31/444 ; A61K31/4427 ; C07D213/75 ; C07D405/14 ; A61P35/00 ; A61K31/497
Abstract:
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
Public/Granted literature
- US20190105309A1 Formylated N-heterocyclic derivatives as FGFR4 inhibitors. Public/Granted day:2019-04-11
Information query
